Search Weight Loss Topics:




Apr 8

Alzheimer’s may have once spread from person to person, but the risk today is low – Monash Lens

Hgh Comments Off on Alzheimer’s may have once spread from person to person, but the risk today is low – Monash Lens

An article published recently in the prestigious journal Nature Medicine documents whats believed to be the first evidence that Alzheimers disease can be transmitted from person to person.

The finding arose from long-term follow-up of patients who received human growth hormone (hGH) that was taken from brain tissue of deceased donors.

Preparations of donated hGH were used in medicine to treat a variety of conditions from 1959 onwards including in Australia from the mid-60s.

The practice stopped in 1985 when it was discovered about 200 patients worldwide who had received these donations went on to develop Creuztfeldt-Jakob disease (CJD), which causes a rapidly progressive dementia. This is an otherwise extremely rare condition, affecting roughly one person in a million.

CJD is caused by prions infective particles that are neither bacterial or viral, but consist of abnormally folded proteins that can be transmitted from cell to cell.

Other prion diseases include kuru, a dementia seen in New Guinea tribespeople caused by eating human tissue, scrapie (a disease of sheep), and variant CJD or bovine spongiform encephalopathy, otherwise known as mad cow disease. This raised public health concerns over the eating of beef products in the United Kingdom in the 1980s.

Read more: People who lived in the UK in the 'mad cow disease' years may now be able to give blood. The risk of vCJD is tiny

Human growth hormone (hGH) is produced in the brain by the pituitary gland. Treatments were originally prepared from purified human pituitary tissue.

But because the amount of hGH contained in a single gland is extremely small, any single dose given to any one patient could contain material from about16,000 donated glands.

An average course of hGH treatment lasts about four years, so the chances of receiving contaminated material even for a very rare condition such as CJD became quite high for such people.

hGH is now manufactured synthetically in a laboratory, rather than from human tissue. So this particular mode of CJD transmission is no longer a risk.

The Nature Medicine paper provides the first evidence that transmission of Alzheimers disease can occur via human-to-human transmission.

The authors examined the outcomes of people who received donated hGH until 1985. They found five such recipients had developed early-onset Alzheimers disease.

They considered other explanations for the findings, but concluded donated hGH was the likely cause.

Given Alzheimers disease is a much more common illness than CJD, the authors presume those who received donated hGH before 1985 may be at higher risk of developing Alzheimers disease.

Alzheimers disease is caused by presence of two abnormally folded proteins,amyloid and tau. Theres increasing evidence these proteins spread in the brain in a similar way to prion diseases. So the mode of transmission the authors propose is certainly plausible.

However, given the amyloid protein deposits in the brain at least 20 years before clinical Alzheimers disease develops, theres likely to be a considerable time lag before cases that might arise from the receipt of donated hGH become evident.

Read more: Size of brain area linked with cognitive decline even in people with no other warning signs of Alzheimers disease

In Australia, donated pituitary material was used from 1967 to 1985 to treat people with short stature and infertility.

More than 2000 people received such treatment. Four developed CJD, the last case identified in 1991. All four cases were likely linked to a single contaminated batch.

The risks of any other cases of CJD developing now in pituitary material recipients, so long after the occurrence of the last identified case in Australia, are considered to be incredibly small.

Early-onset Alzheimers disease (defined as occurring before the age of 65) is uncommon, accounting for about 5% of all cases. Below the age of 50 its rare and likely to have a genetic contribution.

The Nature Medicine paper identified five cases that were diagnosed in people aged 38 to 55. This is more than could be expected by chance, but still very low in comparison to the total number of patients treated worldwide.

Although the long incubation period of Alzheimers disease may mean more similar cases may be identified in the future, the absolute risk remains very low. The main scientific interest of the article lies in the fact its first to demonstrate that Alzheimers disease can be transmitted from person to person in a similar way to prion diseases, rather than in any public health risk.

The authors were keen to emphasise, as I will, that Alzheimers cannot be contracted via contact with, or providing care to, people with Alzheimers disease.

Read more: Young-onset Alzheimers can be diagnosed from as early as 30 and the symptoms are often different

This article originally appeared on The Conversation.

Follow this link:
Alzheimer's may have once spread from person to person, but the risk today is low - Monash Lens

Related Posts

    Your Full Name

    Your Email

    Your Phone Number

    Select your age (30+ only)

    Select Your US State

    Program Choice

    Confirm over 30 years old

    Yes

    Confirm that you resident in USA

    Yes

    This is a Serious Inquiry

    Yes

    Message:



    matomo tracker